Vascular Interventional Advances (VIVA)

The VIVA Foundation is a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education, research, advocacy, and collaboration. It hosts the VIVA (Vascular InterVentional Advances) and The VEINS (Venous Endovascular INterventional Strategies) annual conferences. The VIVA Foundation also presents the Vascular Leaders Forum and collaborates with other industry-leading groups to move the field forward. 

Medtronic’s IN.PACT Admiral DCBs

Drug-coated balloons an effective tool in the battle against femoropopliteal disease

Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes. 

Thumbnail

Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients

The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas. 

Many PAD patients are missing out on vital risk assessments

The findings, based on Medicare data, were presented at VIVA21 in Las Vegas.

Arizona patients successfully receive the world’s first bioconvertible IVC filter commercially offered in US

BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter.

New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD

Medtronic data presented today reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries.

The Eluvia drug-eluting stent continues to demonstrate positive outcomes in long lesion IMPERIAL sub-study

Boston Scientific announced clinical outcomes from the IMPERIAL Long Lesion Sub-study demonstrating that the Eluvia Drug-Eluting Vascular Stent System is safe and effective in treating patients with long, complex, calcified lesions within the superficial femoral and proximal popliteal arteries.

New $1 million research initiative supports early career vascular disease investigator research

The American Heart Association and VIVA Physicians, Inc. announced today a two-year $1 million grant program to support research initiatives in vascular disease and career development opportunities for early career investigators at the post-doctoral level.

Data Further Reinforce IN.PACT Admiral DCB as Frontline Option to Address Treatment Challenges in PAD

DUBLIN and LAS VEGAS — September 12, 2017 — Medtronic plc (NYSE: MDT) data announced today reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD).

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup